Physician‐assessed improvement in rosacea severity · Participants with rosacea
Metronidazole probably leads to higher physician‐assessed improvement in rosacea severity compared with placebo (moderate certainty).
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
QoL · Participants with rosacea
Topical ivermectin leads to higher HRQOL DLQI, proportion of participants that reported at end of study… compared with topical metronidazole (high certainty).
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
Topical ivermectin leads to higher participant‐assessed improvement in rosacea severity Likert scale ‐… compared with topical metronidazole (high certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Topical ivermectin showed no clear difference in proportion of participants with adverse event compared with topical metronidazole (moderate certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Topical ivermectin leads to higher physician‐assessed improvement in rosacea severity compared with topical metronidazole (high certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL Ocular Surface Disease Index (scale 0 to 100, 100 worst) · Participants with ocular rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with ocular rosacea
Ciclosporin ophthalmic emulsion 0.05% showed no clear difference in proportion of participants with adverse event compared with artificial tears (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity Schirmer score · Participants with ocular rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL RosaQoL · Participants with rosacea
1 finding from 1 review